Transcription Elongation Factor ELL2 Drives Ig Secretory-Specific mRNA Production and the Unfolded Protein Response

Kyung Soo Park, Ian Bayles, Alec Szlachta-McGinn, Joshua Paul, Julie Boiko, Patricia Santos, June Liu, Zhou Wang, Lisa Borghesi and Christine Milcarek

*J Immunol* 2014; 193:4663-4674; Prepublished online 19 September 2014; doi: 10.4049/jimmunol.1401608
http://www.jimmunol.org/content/193/9/4663

Supplementary Material
http://www.jimmunol.org/content/suppl/2014/09/19/jimmunol.1401608.DCSupplemental

References
This article cites 48 articles, 24 of which you can access for free at:
http://www.jimmunol.org/content/193/9/4663.full#ref-list-1

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Author Choice
Freely available online through *The Journal of Immunology*
Author Choice option

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Transcription Elongation Factor ELL2 Drives Ig Secretory-Specific mRNA Production and the Unfolded Protein Response

Kyung Soo Park,*† 1 Ian Bayles,*† 1 Alec Szlachta-McGinn,* Julie Paul,*† 1 Zhou Wang, ‡ Lisa Borghesi,* and Christine Milcarek*†

Differentiation of B cells into Ab-secreting cells induces changes in gene transcription, IgH RNA processing, the unfolded protein response (UPR), and cell architecture. The transcription elongation factor eleven nineteen lysine-rich leukemia gene (ELL2) stimulates the processing of the secreted form of the IgH mRNA from the H chain gene. Mice (mus musculus) with the ELL2 gene floxed in either exon 1 or exon 3 were constructed and crossed to CD19-driven cre/CD19⁺. The B cell-specific ELL2 conditional knockouts (cKOs; ell2lox⁺/lox⁺ CD19cre/+ ) exhibit curtailed humoral responses both in 4-hydroxy-3-nitrophenyl acetyl–Ficoll and have a paucity of secreted IgH; and have distended, abnormal-appearing endoplasmic reticulum. IRE1α is efficiently phosphorylated, but the amounts of Igk, κ, AT6, BiP, Cyclin B2, OcaB (BOB1, Pou2af1), and XBP1 mRNAs, unspliced and spliced, are severely reduced in ELL2-deficient cells. ELL2 enhances the expression of BCMA (also known as Tnfrsf17), which is important for long-term survival. Transcription yields from the cyclin B2 and the canonical UPR promoter elements are upregulated by ELL2 cDNA. Thus, ELL2 is important for many aspects of Ab secretion, XBP1 expression, and the UPR.


A ctivation of B cells by cognate Ag or polyclonal stimulators like LPS results in a large shift in RNA processing to the secretory-specific form of IgH chain mRNA (1) and to a considerable upregulation of the unfolded protein response (UPR) to accommodate the massive quantity of IgH protein that results (2). This also causes major structural accommodations and altered endoplasmic reticulum (ER) cellular architecture. B cell expansion follows after LPS or Ag stimulation to initially create extrafollicular plasmablasts. B cells can also enter the follicles and form germinal centers where memory and plasma cells (PCs) can form (3). Long-lived PCs can reside in the bone marrow where they express a number of receptors for survival factors (4). Opposing suites of transcription factors either maintain the B cell program (e.g., Pax5, Bach2, Bcl6) or promote and facilitate differentiation to Ab secretion (e.g., IRF4, Blimp1, XBP1) (5). The mRNA for transcription elongation factor eleven nineteen lysine-rich leukemia gene (ELL2) was elevated when Blimp-1 and IRF4 were turned on (2, 6, 7); we showed that addition to B cells of exogenous cDNA for ELL2 stimulates alternative RNA processing, resulting in the use of the IgH secretory-specific poly(A) site and the skipping of weak alternative exons in IgH and test substrates (1). ELL2 drives the association of positive transcription elongation factor b (pTEFb) to RNA polymerase II (RNAPII), thereby stimulating phosphorylation of ser-2 on the C termini of the elongating polymerase near the start of the IgH locus (1, 8, 9). Thus, the binding of ELL2 with the highly phosphorylated C-terminal domain of RNAPII, polyadenylation factors, Dot1L (the histone H3K79 methylase), and with histone H3 K79me3 modifications are all seminal to the changes in RNA processing seen at the IgH locus. However, it was not known whether ELL2 is required for secretion IgH production in the animal and at what stage.

It was also not known whether the related members in the ELL family could substitute for ELL2. Three mammalian ELL genes encode proteins that are engaged in transcription elongation with pTEFb and RNAPII (10). ELL1 is ubiquitously expressed, whereas ELL3, found in stem cells (11) and in unstimulated B cells (12), is reduced upon LPS stimulation. ELL2, and not the other ELLs, was
found in the superelongation complex associated with HIV-1 TAR and Tat with pTEFb (13). ELL2 is elevated in PC differentiation (1) and germlinal center cells, and is highly expressed in all myeloma cells surveyed for survival along with IRF-4 (6), making it unique among its related family members. We therefore reasoned that deleting ELL2 specifically in B cells could alter the production of the IgH secretory-specific mRNA after activation of those cells.

Two different ELL2 conditional knockout (cKO) mice were generated, one in exon 1 and one in exon 3; both models showed impaired PC differentiation in vivo and in vitro. The endogenous levels of serum Ig were decreased in the CD19 cre-driven conditional ELL2 knockout mice. These mice showed impaired responses to immunizations with 4-hydroxy-3-nitrophenyl acetyl (NP)-Ficoll, a T-independent Ag, or NP-keyhole limpet hemocyanin (KLH), a T-dependent Ag; Ag-specific Ig production was significantly reduced in the knockouts relative to wild type (wt) mice. Recall responses were also affected. The splenic transitional 3 (T3) cells and PCs were significantly reduced in the cKOs, whereas bone marrow responses were also affected. The splenic transitional 3 (T3) cells and BCMA were also impaired in the knockouts. Thus, ELL2 is a key player not only in IgH mRNA processing, but also in subsequent Ab-secreting cell differentiation, making it exceptional in the ELL family of factors and crucial for PC development.

Materials and Methods

Generation of cKO mice

ELL2 is a single gene that resides on mouse chromosome 13. In collaboration with genOway (http://www.genoway.com), ~1 kb upstream of the transcription start site and a 1–50 of exon 1 were surrounded by loxp sites in a conditional targeting vector (Fig. 1A), the vector was inserted into the genome in embryonic stem (ES) cells (129Sv/pas) and insertion of the construct selected for the neomycin marker in the targeting vector; the neo cassette was flanked by frt sites (see Supplemental Fig. 1 for the Southern blots showing proper integration into the ELL2 gene). The ELL2 gene and subsequent deletion was also detected by PCR (Fig. 1). After germline transmission of the targeted allele was established, the flanked neo cassette was removed by crossing to mice expressing Flpe. The mice were made homozygous for the exon1 loxP/loxP locus, then crossed to CD19 cre mice (129Sv/pas), and insertion of the construct selected for the neomycin marker in the targeting vector; the neo cassette was flanked by frt sites (see Supplemental Fig. 1 for the Southern blots showing proper integration into the ELL2 gene). The wt allele produces a PCR band of 1806 bp, insertion of loxp produces a fragment of ~477 bp, whereas the CD19 cre shows a fragment of 100 bp. Heterozygotes show both bands. The condition is the same as in the genotyping of ELL2. Isolation of genomic DNA was done using whole-blood samples collected from tail-vein bleeds using DNeasy Blood and Tissue Kit (5003; Qiagen) according to the manufacturer’s instructions.

Mice were maintained at the University of Pittsburgh animal facilities, and experiments were undertaken and conducted in accordance with institutional policies, as per Animal Welfare Assurance number A1387-01.

Flow cytometry

Bone marrow and spleen were harvested from mice and processed as previously described (14, 15). Cell staining was performed using Abs to murine surface markers obtained from eBioscience or BD Pharmingen. Primary anti-mouse Abs were B220 (clone RA3–6B2), CD19 (clone MB19–1), CD43-PE (clone 57), AA4.1 (clone AA4.1), IgM (clone 331), IgD (clone 11-26), CD138 (clone 281-2), CD21 (clone eBios9), CD23 (clone B3B4), CD5 (clone 53-7-3). Secondary reagents were streptavidin-Cy7PE and streptavidin-eFluor 450. Dead cells were excluded using DAPI. Flow cytometry was performed on a 4-laser, 12-detector LSR Fortessa (BD Biosciences). Data were analyzed using FlowJo software. The schemes were derived from Santos et al. (16) and Winkelmann et al. (17), and are described more fully in Supplemental Table 1.

To sort cells for Ab-secreting PCs, we incubated LPS-induced splenocytes with allopurinol-conjugated Anti-Human/Mouse CD45R (B220; #47-0452; eBioscience) and PE-conjugated Rat Anti-Mouse CD138 (8553714; BD Biosciences) for 30 min on ice in the dark. Dead cells were excluded by DAPI staining. BCMA staining was done using Monoclonal Anti-mouse BCMA-Fluorescein (6F8B593F; RD Systems).

ELISA

Assays were performed following standard procedures using Clonotyping System-AP (Southern Biotech, Birmingham, AL) on the 96-well plates (Dynex Immulon HB, Chantilly, VA). The kit IgG2c antisera is necessary for the C57BL/6 mice that lack IgG2a (18). The plate was coated with 100 µl/well capture Ab (Goat anti-mouse IgG H+L) to a concentration of 5 µg/ml in 1× PBS, pH 7.4. After overnight incubation at 4°C, the wells were treated with 10% BSA for 3 h at room temperature. Mouse serum was diluted 5000 times for IgG1 or 1000 times for other Ig isotypes and incubated with the plates overnight at 4°C. The wells were washed and alkaline phosphatase (AP)-labeled detection Abs (diluted 5000 times) were added and incubated for 1 h at room temperature. The wells were washed and developed using 1 mg/ml AP Substrate solution (Thermo Scientific, Waltham, MA) containing p-nitrophenyl phosphate for ~15 min. The plate was read at A450. Standards were run for the various isotypes. For NP-specific Ig detection, plates were coated with NP-BSA (Biosearch Technologies, Petaluma, CA).

Immunizations

Six- to 8-week-old ELL2 cKO mice and littermate control mice were immunized i.p. with either NP-Ficoll (F1420; Biosearch Technologies) at 25 µg in 0.1 ml PBS or 100 µg NP-NH2 (N-5060; Biosearch Technologies) preincubated with alum (77161; Pierce) as previously described for blimp knockouts (19). Serum was collected at 1, 2, and 3 wk postinjection using NP-BSA-coated plates in an ELISA. For the recall response, the same dose
Western blot

Protein samples were obtained from nuclear and cytoplasmic extracts of 0 d and 3 or 4 d after LPS exposure using NE-PER Nuclear and Cytoplasmic Extraction Reagents (#78833; Thermo Scientific) according to the manufacturer’s instructions. Protein samples were then measured for concentration by Bradford Assay. Western protocol followed was the Bio-Rad General Protocol for Western blotting (Bio-Rad Bulletin 6376 Rev A). m.w. markers used in the gels were the Precision Plus Protein Kaleidoscope markers from Bio-Rad (#161-0375). Before running protein samples on 10% Acrylamide Mini-PROTEAN TGX precast Gels (Bio-Rad Laborato-
ries #456-1034), samples were boiled at 95°C for 5 min and centrifuged at 16,000 × g in a microcentrifuge for 1 min. Samples were then loaded onto gels and run for 5 min at 50 V. The voltage was then increased to 165 V for ~1 h. After gels had run to desired length, the gel was placed in a 1X transfer buffer (25 mM Tris, 190 mM glycine 20% methanol, 1% SDS) for 15 min. After transfer to polyvinylidene fluoride membrane, samples were an-
alyzed by immunoblot and visualized by ECL using Pierce ECL Western blotting Substance (#32209; Thermo Scientific). Blots were imaged on a ProteinSimple FluorChem M System.

Abs used

Primary Abs. Primary Abs used included XBP1 (M-186; sc-7160; Santa Cruz Biotechnology) m.w. 29/40 kDa; pAb anti-IRE1α [p Ser 724] Ab (NB100-2323; Novus Biologicals) m.w. 110 kDa; Rh pAb to IRE1α (ab37073; Abcam); ELL2 R4502 affinity-purified rabbit Ab (1); ATF-6 (NB100-2323; Novus Biologicals) m.w. 110 kDa; Rb pAb to IRE1α (NB100-2323; Novus Biologicals) m.w. 75 kDa; Anti-Mouse IgM (μ-chain–specific) Ab produced in goat (M8644-1MG; Sigma) m.w. >53kDa; Anti-Hu/Mo Blimp1 purified clone: 6D3 (14-5963-82; Biococoon); m.w. 110 and 150 kDa with sumolation; IgM (κ-chain–specific) m.w. 25 kDa; Cyclin B2 (H-105; sc-22776; Santa Cruz Biotechnology) m.w. 45kDa; Y11 (H-414; sc-1703; Santa Cruz Biotechnology); Monoclonal Mouse Anti-Actin Clone C4 (691001; MP Biologicals) m.w. 43 kDa.

Secondary Abs. Secondary Abs used included goat anti-rabbit IgG-HRP (sc-2004; Santa Cruz Biotechnology); donkey anti-goat IgG-HRP (sc-2020; Santa Cruz Biotechnology); goat anti-mouse IgG-HRP (sc-2005; Santa Cruz Biotechnology); and goat anti-rat IgG-HRP (sc-2006; Santa Cruz Biotechnology).

ELISPOT

Millipore Multiscreen 96-well Filter Plates (#MSIPS4W10; Millipore) were coated with 5–6 μg/ml goat anti-mouse H and L chain, purified Igs (#5300-04; Southern Biotech) for 2 h at room temperature (RT). Wells were then washed and blocked with cell media + 10% FCS for 1 h at RT. Live cells (sorted with DAPI), after 72 h post LPS exposure (20 μg/ml), were then added to the wells and allowed to incubate overnight at 37°C. After incubation with Goat anti-mouse IgM-AP Ab (#5300-04; Southern Biotech) for 15 min at RT, spots were visualized with 1-Step NBT/BCIP solution (#34042; Thermo Scientific). Counting and imaging of spots was done on an ImmunoSpot S6 Micro Analyzer using Immunospot 5.0 Professional software. For bone marrow samples, anti-IgG1-AP Ab was used.

B cell cultures

Splenocytes were extracted from mice and naive B cells selected by auto-
MACS using a B cell Isolation Kit (#130-090-862; Miltenyi Biotec) using a mixture of biotin-conjugated Abs against CD43 (Ly-48), CD4 (L3T4), and Ter-119, as well as Anti-Biotin MicroBeads. The splenocytes were counted and then coated with 5–6 μg/ml goat anti-mouse mAb and cultured at a density of 1–5 × 10^6 cells/ml. Cells were cultured for 72 or 96 h with LPS at 20 μg/ml (LPS from Escherichia coli 0111:B4; #L3012-10MG; Sigma) in RPMI 1640 media with 50 μM 2-ME, 2 mM glutamine, 10% FCS, sodium pyruvate, nonessential amino acids, Pen/Strep, and HEPES buffer. A cell density of 1–5 × 10^6 cells/ml was maintained by dilution in medium with LPS.

RNA isolation and RT-QPCR

NucleoSpin RNA II kits (740955.50; Clontech) were used to isolate RNA from cells at 0 and 7296 h after LPS exposure. To create cDNA SuperScript First-
 Strand (#11904-018; Invitrogen), kits were used according to manufacturer’s instructions and dT primers. cDNA was then used in RT-quantitative PCR (qPCRs) using SYBR Green PCR Master Mix (4309155; Applied Bio-
systems) reagents. Primers used for RT-qPCR are listed in Supplemental Table 2.

Luciferase

The mouse cyclin B2 promoter (-1188) cloned into the firefly luciferase pGL4.10 vector at the KpnI and NcoI sites was a generous gift of Dr. Kurt Engeland, Universitat Leipzig, Germany. This is similar to the previous cyclin constructs in which the inhibitory effect of p53 was demonstrated on the cyclin B2 promoter (cKO). We cloned portions of the human cyclin B1 promoter (-2973 to 0), ELL2 (-3000 to 0), and IRF4 (-2182 to 0) promoters into pGL4.11 (Promega, Madison, WI). The expression cDNA plasmids for b淋1-1 (CM#632), c-Myc (CM#633), ELL2 [CM#56 7 (11)], IRF4 (CM#594), p53 wt (CM#634), mutant p53R175H (CM#635), and the p65 subunit of NF-κB (Dr. Guitan Xiao, University of Pittsburgh Cancer Institute) were transfected in 12-well plates (Falcon, Franklin Lakes, NJ) with the indicated reporters in 20% C3T cells using GenJuice (Novagen, San Diego, CA) as the transfection reagent. After 2 d, cells were lysed with 0.1% NP40/0.1% SDS in lysis buffer. The p-value was determined by a two-tailed Student t test when two samples were analyzed, or in the case of multiple samples, using ANOVA with Tukey’s or Bonferonni’s posttests. Error bars represent SEM.

Results

cKO of ELL2 in B cells

Mice deficient in ELL1 (also known as MEN1) are embryonic lethal (24). To avoid the lethality that might accompany a complete loss of ELL2 in mice, we deleted ELL2 specifically in B cells. The strategy we used to make and detect deletions is shown in Fig. 1A and described more completely in Materials and Methods, whereas the Southern blots showing proper integration are shown in Supple-
mental Figure 1. We independently targeted exon 1 in one strain of mice and exon 3 in another, because we were initially concerned that the loxP insertion in the ELL2 promoter region might com-
promise normal ELL2 expression elsewhere. Mice bearing the ELL2 exon 1 loxP/loxP and exon 3 loxP/loxP genotypes, diagramed in Fig. 1A, were crossed with mice carrying one copy of the cre recombinase coding sequence, driven by the B cell–specific CD19 promoter designated CD19^cre/+. As illustrated in Fig. 1B, the deletion that occurs in splenic B cells of exon 1 in the ELL2 cKO, generating the shorter 0.6-kb PCR product, is >90%. The ELL2 exon 3 loxP/loxP is also deleted in splenic B cells of mice carrying that insert (see Fig. 1C). In this assay, the specific PCR product encompassing the 5’ loxP site is virtually absent in the ELL2 exon 3 floxed splenic B cells, with the PCR product corresponding to the GAPDH gene serving as a positive loading control (see a later figure for a more complete deletion). To assess ELL2 protein expression in the cKO mouse (ELL2^floxp/loxP CD19^cre/+), we purified and stimulated B220^ resting splenocytes with LPS for 3 or 4 d, a treatment that normally induces B cell proliferation and PC differentiation. When compared with control (ELL2^loxP/loxP CD19^+/+) or ELL2^loxP/loxP CD19^+/+) spleenocytes treated the same way, there was very little or no ELL2 protein expression in the cKO mice (Fig. 1D). The RNA from splenic B cells was isolated with and without 4 d of LPS exposure. The level of HPRT mRNA (set as 100%) was used as an internal RT-PCR control. As shown in Fig. 1E, the mRNA for ELL2 increases >6-fold relative to no LPS in the control mouse spleens, achieving levels greater than HPRT mRNA,

"The Journal of Immunology" 4665

Downloaded from http://www.jimmunol.org/ by guest on April 14, 2017
a housekeeping gene that is consistently expressed throughout B cell differentiation (26). The mRNA for ELL2 does not increase after LPS in either the ELL2 exon 1 or the exon 3 targeted mice, consistent with the gene deletion and protein results. Thus, the cre/loxP strategy is effective at eliminating ELL2 expression in these late stages of B cell development.

**Reduction in Ig secretion in ELL2loxP/loxP CD19cre/+ mice**

To determine whether ELL2 has an effect on Ig secretion in the animal, we then conducted ELISA assays for the amount of secreted Ig in the serum of unimmunized control ELL2loxP/loxP CD19+/+ or ELL2+/+ CD19cre/+ mice (combined data labeled wt on graphs) and the ELL2loxP/loxP CD19Cre/+ mice (cKO). We saw a decrease in the ELL2 exon 1 cKOs in serum levels of secreted IgM, IgG1, and IgA isotypes as shown in Fig. 2 and for all the other IgG isotypes (data not shown). With the ELL2 exon 3 cKO mice, the Ig levels were decreased $\approx 2$-fold for IgM, IgG1, and IgA (Fig. 2), as well as for the other IgG isotypes (data not shown). ELL2 expression on stimulated B cells is thus required for Ig secretion in the whole animal.
The effect of the cKO of ELL2 is even more evident when the system is challenged by Ag. Mice with a cKO of exon 3 of ELL2 (cKO) between 7 and 8 wk of age were immunized with NP-Ficoll, and serum was drawn at 1, 2, and 3 wk after immunization. ELISAs for NP-specific Abs were conducted. As summarized in Fig. 3, there was significantly less anti-NP Ab of the IgM, IgG2b, and IgG3 isotypes in the exon 3 cKO mice relative to control mice. Next we immunized naive exon 3 ELL2 cKO and control mice with NP-KLH, an Ag that requires T cell help for the B cell responses. As shown in Fig. 3, there was a significantly lower amount of specific anti-NP Ab in the exon 3 NP-KLH–immunized cKO mice of the IgM, IgG1, IgG3, and IgG2c isotypes relative to the control mice. Other isotypes in exon 3–targeted mice were also decreased (data not shown). Thus, we conclude that deletion of ELL2 in stimulated B cells impairs the specific Ab responses to the T-independent Ag, NP-Ficoll, and to the T-dependent Ag, NP-KLH. Upon restimulation with NP-KLH, we observed a recall response in the control mice that was decreased in the cKO mice; data for IgG2c are shown in Fig. 3. Thus, ELL2 is important for Ag-specific responses and immunological memory.

B cell subsets in vivo

The cell-surface markers used for this study are summarized in Supplemental Table I. Analysis by flow cytometry for both the exon 1 and the exon 3 cKO naive mice indicates that there is no significant change in B cell numbers, B1 versus B2 ratios, T cells, or their distribution (data not shown). However, when the ELL2 exon 3–targeted mice were challenged with Ag (NP-Ficoll or NP-KLH), there was a significantly higher percentage of immature and recirculating B cells in the bone marrow after immunization than in the control (Fig. 4). There is a trend to fewer T1 and T2 type B cells in the spleen and a significant decline in T3 cells in the cKOs (Fig. 4B). The Immunological Genome Project (http://immgen.org) profile for ELL2 shows that it is expressed at an intermediate level in these cells. When we determined the number of CD138+ cells, we saw a significant decline in their numbers in the immunized exon 3 ELL2lox/lox CD19lox/lox mice relative to control mice treated the same way. With the loss of ELL2 in B cells, differentiation can continue to the B220* IgM+ (new B cell) stage, but the increase in recirculating cells in the bone marrow shown in Fig. 4A indicates a potential problem with further maturation in the spleen, which is evident in the lower numbers of T3 and CD138+ cells produced. We performed ELISPOTS on bone marrow cells from unimmunized exon 1 and exon 3 ELL2 cKO mice using anti-IgG1 Abs. As shown in the results enumerated in Table I, there were significantly fewer IgG1-producing cells in the bone marrow of the cKO mice. These IgG1 cells may represent long-lived PCs or memory B cells (27).

ELL2 deletion influences IgH processing and PC differentiation

After ex vivo LPS stimulation of the naive splenic B cell population in both exon 1 and exon 3 floxed, ELL2 cKOs as compared with CD19+/+ controls, we noted a decrease in the production of B220+CD138+ cells. As shown in a representative experiment in Fig. 5A with an exon 3–deficient mouse, there were ∼4-fold fewer cells in the conditional knockout. The cells that had become B220+CD138+ were sorted and analyzed by PCR to determine whether they were still deleted for exon 3 of ELL2. They were still deficient in ELL2 and do not represent the progeny of a population of undeleted cells (Fig. 5B). The cKO and control cells were equally viable during the course of all the LPS stimulation experiments with both types of cKOs. We isolated RNA from the B220+CD138+ cells of the two different ELL2 exon knockouts and the control, and subjected the samples to RT-QPCR as described in

FIGURE 2. Serum levels in naive ELL2lox/lox CD19+/+ mice are reduced with both exon 1 and exon 3 deletions. Control mice with either ELL2lox/lox CD19+/+ or ELL2lox/lox CD19lox/lox (filled symbols, wt) and the ELL2lox/lox CD19lox/lox mice (open symbols, cKO) were bled at 7, 12, and 17 wk. Serum was analyzed by ELISA for the indicated isotypes. *p = 0.05, **p = 0.01, or ***p = 0.001 as indicated on graphs.
Materials and Methods. We compared RNA from naive B cells and normalized all the values to HPRT, which had previously been shown to remain constant throughout the B-to-PC transition (28). Production of the secretory-specific IgH mRNA is induced dramatically in the control ELL2+ cells as expected. In the knockout mice, there was no induction of the secretory-specific H chain mRNA. The overall level of IgH mRNA is reduced in the ELL2 cKO as well; compare the total amount of IgH mRNA secretory-specific plus IgH mb (Fig. 5D and Tables II, III) in the cKO versus the control. Therefore, ELL2 drives up the amount of mature IgH mRNA, as well as influencing processing. We also saw a decrease in Igκ mRNA relative to the control (Fig. 5D). Cyclin B2 mRNA was also not as robustly induced in the cKO mice relative to the control B220loCD138+ cells. Examination of XBP1 mRNA revealed a dramatic decrease in both total mRNA and the specifically cytoplasmic spliced form that results from induction of the IRE1 phosphorylation. An ELISPOT to measure IgM secretion, conducted with the B220hiCD138+ cells after 4 d of LPS, shows
a 4.4-fold decreased number of spots, many of which are less intense than those in the control, indicating decreased secretion of IgM in the ELL2 cKO (Fig. 5E and Table I). Thus, as we had predicted based on our previous studies (1), ELL2 is essential for efficient processing to the secretory form of IgH in PCs; in the absence of ELL2, the change-over in RNA processing does not occur, and secreted IgH $\mu$ is not induced. In addition, other mRNAs were also reduced in the cKO mice (Table II); these include several in the unfolded response pathway like ATF6, BiP, and OcaB, the transcription of which are thought to be driven by XBP1 (29). BCMA (also known as Tnfrsf17) surface expression is diminished in the ELL2 cKO relative to wild type (wt), as shown in Fig. 5D. Expression of IRF4 and blimp-1 were at or above control levels in the ELL2 cKO B220loCD138+ cells (Table II), so those early steps in B cell activation are largely intact.

The sorted B220loCD138+ cells were fixed and analyzed in the transmission electron microscope (Fig. 6). The cKO cells display an ER that is dilated and fragmented. Similar, distended ER is seen in XBP1 knockout PCs (30). Based on the accumulated data, we conclude that ELL2 deletion has a significant impact on IgH secretory mRNA and protein, XBP1 production, and the activated cell architecture.

We then examined the expression of a number of other mRNAs and proteins in the bulk population of control and conditional ELL2 knockout LPS-stimulated cells. We observed normal decreases in some mRNAs that accompany early steps in PC differentiation; compare plus versus minus LPS values, like ELL3 and C/ebp-$\beta$ (Table III). Some mRNAs are induced after LPS, both in control and the cKOs like AICDA, PCNA, and Eaf2, a factor associated with the ELL2:pTEFb complex, although their overall levels at the induced state are somewhat less than control. We observed no significant change in the expression of some “housekeeping” genes like Hif1-$\alpha$ and Hsp40 in either the controls or the knockouts. A majority of the probes used in the RT-QPCR spanned exons. When we examined the splicing patterns of several of these genes (Bip, Eaf2, IRF4), we saw no difference between control and the ELL2-deficient cells before or after LPS stimulation (data not shown). Thus, some aspects of the PC program are operative. The induction of cyclin B2 mRNA seen in control LPS-stimulated cells was lacking in the cKOs. Cyclin B2 protein resides in the Golgi (31) where carbohydrates are added to secreted proteins; this suggests that the Golgi may also be affected by the lack of a normal UPR.

Changes in mRNA expression were confirmed by analysis of the protein in both exon 1 and exon 3 cKOs. In Fig. 7, protein results from the exon 3 mice are presented. The unconventionally spliced mRNA of XBP1 (XBPs) encodes a protein (32) of $\sim40$ kDa that acts as a transcription factor for upregulation of the UPR genes (33). Because the unconventional XBP1 splicing is initiated by the IRE1-$\alpha$ protein after its aggregation and phosphorylation by endo-

---

**FIGURE 4.** ELL2$^{loxp/loxp}$ CD19$^{cre/+}$ mice have increased naive bone marrow cells and decreased T3 and PCs in the spleen. (A) Bone marrow and spleen were harvested from mice 21 d after NP-Ficoll or NP-KLH immunization and were subjected to flow cytometry using the indicated Abs. The surface markers used to designate each population are indicated in Materials and Methods and Supplemental Table II. (B) The number of cells in each of the harvested categories was quantified using the flow data. Error bars are ± SEM. *$p = 0.05$, **$p = 0.01$.

---

**Table I. ELISPOT data, splenic B cells, and bone marrow**

<table>
<thead>
<tr>
<th>Bone Marrow IgG1+</th>
<th>Splenic IgM+, B220loCD138+ Sorted 3-d LPS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No. of Spots</strong></td>
<td><strong>Statistics</strong></td>
</tr>
<tr>
<td>Control</td>
<td>66 ±35 SD</td>
</tr>
<tr>
<td>cKO ELL2</td>
<td>9 ±7 SD</td>
</tr>
<tr>
<td>$p$</td>
<td>$2.6 \times 10^{-5}$</td>
</tr>
</tbody>
</table>

Values normalized to 100,000 cells. The $p$ value is determined by two-tailed t tests. $n \geq 6$ per group.
plasmic reticular stress (34, 35), we investigated the amount and state of IRE1 in our cultures. The level of IRE1 mRNA is only slightly reduced in the conditional ELL2 knockouts relative to the control (Table III). The level of phosphorylated IRE1 protein was determined by Western blotting using anti-pSer724 IRE1 Ab (Fig. 7); increases relative to naive B cells were seen in control and cKOs. These bands were confirmed as IRE1 by reaction with a pan IRE Ab (data not shown). Activation of the novel RNase activity of IRE1 is initiated by dimerization-induced trans-autophosphorylation and requires a homodimer of catalytically functional RNase domains (34). When large amounts of protein like secreted Ig or other secretory-associated proteins that may be unfolded are produced, this causes stress to the ER (36). In this study, with reduced levels of BiP, as in the ELL2 cKOs, IRE1 phosphorylation is activated, perhaps in a situation analogous to that of a mutant of IRE1 that cannot bind BiP and remains phosphorylated (37).

Transcription studies

We had previously shown that the alternative processing of the Ig µ H chain is directly regulated by the binding and the action of ELL2 of RNAPII (1). Elongation factors not only change processing patterns, but they also increase the processivity of RNAPII (38), so mRNA yields increase in their presence. We wanted to determine whether ELL2 influences the apparent transcription of some of the other genes we see altered in PC differentiation. We combined ELL2 cDNA with various luciferase reporter constructs

**FIGURE 5.** ELL2lox/lox CD19cre/+ influences B220\(^{lo}\)CD138\(^{+}\) production, IgH secretory mRNA, and XBP1. (A) The flow cytometric profile of the LPS-treated splenic B cells from the cKO mice (left panel) or the controls (right panel). B220\(^{lo}\)CD138\(^{+}\) cells (boxed) were enumerated as a percentage of the total live cell pool and used for subsequent analyses in (B) and (D)-(F). Splenic B cells were treated with 20 µg/ml LPS for 3 d. (B) PCR of the DNA from the sorted cells, exon 3\(^{−}\) mice shown (see Fig. 1 for details). (C) Total cell viability in the LPS culture before sorting was determined by trypan blue staining. (D) RNAs from the sorted B220\(^{lo}\)CD138\(^{+}\) cells were quantified relative to HPRT using real-time QPCR. Probes specific for the various species are indicated in the Supplemental Table II. Control or ELL2 cKO (ELL2lox/lox CD19cre/+). Ig µ H chain mRNA secretory-specific mRNA (IgH mu sec; top) was quantified using probes for the 3’ region in the secretory-specific form. The RT-QPCR probes for Ig κ L chain, cyclin B2, and spliced versus unspliced forms of XBP1 mRNA are indicated in the text or Supplemental Table II. Error bars indicate SEM. *p = 0.05, ***p = 0.001, ****p = 0.0001. (E) ELISPOT. Control or cKO mice spleen cells stimulated with LPS for 3 d and sorted for B220\(^{lo}\)CD138\(^{+}\) (100,000/well) were assayed for the production of IgM with anti-mouse IgM AP Abs and visualized with NBT/BCIP reagent. Spots were counted in an ELISPOT reader and the data enumerated in Table I. (F) Cells in the B220\(^{lo}\)CD138\(^{+}\) selected pools were surface stained for BCMA. Control is with no Ab, WT is the ELL2lox/lox CD19cre/+, ELL2 cKO is ELL2lox/lox CD19cre/+.
Table II. mRNA expression in B220<sup>lo</sup>CD138<sup>+</sup> sorted cells relative to HPRT as 100%.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Control/cKO</th>
<th>Control/cKO</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATF6</td>
<td>313</td>
<td>65</td>
</tr>
<tr>
<td>BiP</td>
<td>1790</td>
<td>536</td>
</tr>
<tr>
<td>Blimp-1</td>
<td>22</td>
<td>25</td>
</tr>
<tr>
<td>ELL1</td>
<td>52</td>
<td>5</td>
</tr>
<tr>
<td>ELL2</td>
<td>2032</td>
<td>&lt;50</td>
</tr>
<tr>
<td>ELL3</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Ire1</td>
<td>272</td>
<td>140</td>
</tr>
<tr>
<td>IRF4</td>
<td>25</td>
<td>32</td>
</tr>
<tr>
<td>Ig µ mb</td>
<td>2138</td>
<td>3093</td>
</tr>
<tr>
<td>OcaB</td>
<td>2680</td>
<td>548</td>
</tr>
</tbody>
</table>

SEM <5% in all cases, not indicated for clarity; n > 3 mice each class, exons 1 and 3. Bolded values show >2-fold change.

Table III. mRNA expression in wt versus cKO ELL2 mice relative to HPRT set as 100% total in the LPS-stimulated cultures at 3–4 d.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Control No LPS</th>
<th>Control 4-d LPS</th>
<th>cKO no LPS</th>
<th>cKO 4-d LPS</th>
<th>Control/cKO 4-d LPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFF1</td>
<td>3</td>
<td>9</td>
<td>0.6</td>
<td>5</td>
<td>1.8</td>
</tr>
<tr>
<td>AICDA</td>
<td>0.6</td>
<td>33</td>
<td>1.8</td>
<td>21.3</td>
<td>1.6</td>
</tr>
<tr>
<td>ATF6</td>
<td>60</td>
<td>320</td>
<td>64</td>
<td>155</td>
<td>2.1</td>
</tr>
<tr>
<td>Bcl6</td>
<td>1.3</td>
<td>5.2</td>
<td>1.3</td>
<td>2</td>
<td>2.6</td>
</tr>
<tr>
<td>BiP</td>
<td>400</td>
<td>1,400</td>
<td>432</td>
<td>308</td>
<td>4.6</td>
</tr>
<tr>
<td>Blimp-1</td>
<td>0.5</td>
<td>48.7</td>
<td>1.0</td>
<td>40.1</td>
<td>1.2</td>
</tr>
<tr>
<td>BRD4</td>
<td>100</td>
<td>190</td>
<td>75</td>
<td>80</td>
<td>2.4</td>
</tr>
<tr>
<td>Cebp-β</td>
<td>87</td>
<td>43</td>
<td>90</td>
<td>27</td>
<td>1.6</td>
</tr>
<tr>
<td>CsfF64</td>
<td>1.5</td>
<td>7</td>
<td>2</td>
<td>3</td>
<td>2.3</td>
</tr>
<tr>
<td>Cyclin B2</td>
<td>15</td>
<td>65</td>
<td>15</td>
<td>8</td>
<td>8.1</td>
</tr>
<tr>
<td>Eaf1</td>
<td>1.8</td>
<td>6.6</td>
<td>2</td>
<td>4</td>
<td>1.7</td>
</tr>
<tr>
<td>Eaf2</td>
<td>7</td>
<td>55</td>
<td>2</td>
<td>35</td>
<td>1.6</td>
</tr>
<tr>
<td>ELL3</td>
<td>37</td>
<td>4</td>
<td>50</td>
<td>3</td>
<td>1.3</td>
</tr>
<tr>
<td>Hif1α</td>
<td>33</td>
<td>22</td>
<td>25</td>
<td>22</td>
<td>1.0</td>
</tr>
<tr>
<td>Hsp40</td>
<td>40</td>
<td>40</td>
<td>38</td>
<td>50</td>
<td>0.8</td>
</tr>
<tr>
<td>IgH mb</td>
<td>3,000</td>
<td>2,900</td>
<td>2,200</td>
<td>6,800</td>
<td>0.4</td>
</tr>
<tr>
<td>IgH sec</td>
<td>5,400</td>
<td>45,000</td>
<td>2,600</td>
<td>1,200</td>
<td>37.5</td>
</tr>
<tr>
<td>Ire1</td>
<td>20</td>
<td>270</td>
<td>20</td>
<td>174</td>
<td>1.6</td>
</tr>
<tr>
<td>IRF4</td>
<td>1.8</td>
<td>21.2</td>
<td>1.7</td>
<td>21.3</td>
<td>1</td>
</tr>
<tr>
<td>NF-xb p50</td>
<td>19</td>
<td>22</td>
<td>22</td>
<td>18</td>
<td>1.2</td>
</tr>
<tr>
<td>NF-xb p65</td>
<td>25</td>
<td>18</td>
<td>6</td>
<td>13</td>
<td>1.4</td>
</tr>
<tr>
<td>Pax5</td>
<td>36</td>
<td>57</td>
<td>35</td>
<td>45</td>
<td>1.3</td>
</tr>
<tr>
<td>PCNA</td>
<td>70</td>
<td>250</td>
<td>150</td>
<td>300</td>
<td>0.8</td>
</tr>
<tr>
<td>Sup5H</td>
<td>4</td>
<td>8.5</td>
<td>4</td>
<td>6.5</td>
<td>1.3</td>
</tr>
<tr>
<td>XB1 total</td>
<td>70</td>
<td>405</td>
<td>71</td>
<td>100</td>
<td>4.0</td>
</tr>
<tr>
<td>XB1 spliced</td>
<td>4</td>
<td>70</td>
<td>3</td>
<td>3</td>
<td>23.3</td>
</tr>
</tbody>
</table>

SEM <5% in all cases, not indicated for clarity; n > 6 mice each class, exons 1 and 3. Bolded values show a greater than 2-fold change.

Discussion

ELL2 floxed conditional deletions, caused by the CD19 promoter–driven cre, decrease basal Ig levels in the serum. In the exon 3 floxed ELL2 cKOs, the responses to immunization with NP-KLH and NP-Ficoll, T-dependent and -independent Ags, respectively, were significantly reduced relative to the controls. In the CD19<sup>flx</sup>– driven deletion of exon 3 floxed ELL2, no gross abnormalities are seen in the number of cells present in the early B cell stages and in total bone marrow and splenic B cells. ELL2 is not maximally expressed until after LPS induction of splenic B cells; thus its expression increases as much as 30-fold. This pattern of expression may explain the lack of influence on the early B cell populations because ELL2 is not maximally expressed until after LPS or Ag induction of splenic B cells. In the spleen, deletion of ELL2 in the total B cell population is >90% in the floxed ELL2 alleles, and this percentage persists after LPS stimulation. The large increase in transcription of ELL2 at a point when the CD19 promoter is very active may explain why the gene is so successfully targeted by CD19<sup>flx</sup>.

After ex vivo LPS stimulation of resting B cells, production of secretary-specific IgH µ is significantly reduced in both exon 1 and exon 3 knockouts as judged by mRNA, protein, and ELISPOT.
analyses. Production of ex vivo LPS-stimulated, splenic B cells that are B220loCD138+ is reduced by at least 4-fold in the cKOs. Those sorted B220loCD138+ cells lack ELL2 by mRNA and genomic DNA analyses, and have a paucity of secreted IgH and XBP1, with distended, abnormal-appearing ER. In the whole animal, the effect of ELL2 deletion on total Ig production is less profound than that we see in vitro. Our in vitro experiments were done with splenic B2 cells, not B1 cells, and after LPS stimulation; engagement of TLR4 is not the only way to trigger Ig production. Thus, other factors may influence secretory Ig production in B1 cells or in other activation pathways in the whole animal.

IRF4, blimp-1, and XBP1 have been identified as important for PC production (5). When a B cell line (L29mu+) was stimulated to convert to the PC phenotype, it did so in a multistep process; proteomic analyses showed that the metabolic capacity and secretory machinery were put into place before the mass production of Ig that normally follows (42). Ig secretion in a blimp-1 knockout is low, indirectly through the downstream effects of pax5 suppressing XBP1 (2). When B cells deficient in secretory-specific μ protein (AID−/− mus−/− or mus−/−) were stimulated with mitogens, they showed reduced ability to differentiate into B220loCD138+ cells and reduced survival (43). But the absence of secretory Ig protein alone did not prevent XBP1 accumulation, or XBP1 splicing, which may normally precede upregulation of secreted Ig (33, 43). The hypothesis that the machinery for secretion is put in place before detectable IgH processing to the secreted form was generated. However, what we see in the ELL2 cKOs is that the two processes (establishment of secretory machinery and IgH mRNA processing) appear linked; overall, XBP1 production is reduced along with IgH. It is clear that lack of ELL2 has broader effects than lack of secretory Ig alone, and our luciferase studies show ELL2 can act on cyclin B2 and genes bearing the UPRE to enhance mRNA levels.

Another group used an siRNA-mediated knockdown of ELL2 mRNA in cultured PCs (12). They showed, using deep mRNA sequencing, that the knockdown of ELL2 influenced IgH processing, and expression of several splicing factors, cyclin B2 (ccnb2), and the B cell maturation Ag (tnfrsf17), also known as BCMA. We saw a decrease in IgH secretory mRNA processing, and cyclin B2 and BCMA levels in LPS-stimulated splenic B cells in our knockout mice. Loss of BCMA can contribute to long-term survival (4), and this may be reflected in the reduced number of IgG1 Ab-secreting cells by ELISPOT we saw in bone marrow cells in the knockouts. We saw no major effects on RNA splicing, but rather a significant impairment in the development of the UPRs, perhaps because ELL2 and secreted Ig are important for the establishment of the UPR, but not necessarily for its maintenance, which could be missed by looking only at established PCs.
In the ELL2 knockouts, IRE1α is phosphorylated, but the expression of the downstream proteins for the UPR including spliced XBP1 is reduced in the LPS-stimulated spleens cells. In mature PCs, the ER response is unique from that seen in other cells (44). The UPR in many cells typically has three arms: the IRE-1/XBP1 pathway, an ATF6 pathway, and the PERK pathway (40). But PERK and ATF6 knockout mice secrete normal amounts of Ig (33, 45). XBP1 conditional deletion mice show defects in PC development (46) and low levels of secretory Ig (47). Thus, when B cells are stimulated, the primary pathway for ER remodeling appears to reside in the IRE1-1 to XBP1 pathway (48). Aggregation and then autophosphorylation of IRE1 cause it to enhance the ability to specifically cleave and then splice XBP1 mRNA; the newly spliced XBP1 mRNA species encodes XBP1 protein with transcriptional activity on its own promoter and other UPR promoters containing the UPRRE (33, 35). However, the low levels of IgM mRNA in XBP1−/− result from the 8-fold increased levels of IRE1P over control; the highly abundant IRE1P cleaves the µ secretory mRNA (49). But a double deletion of XBP1 and IRE1 restores IgM secretion by inhibiting mRNA degradation (49).

Taken together, this leads us to a conclusion that Ig secretion can occur without XBP1 cleavage/splicing, and there may be other proteins that allow for the upregulation of the UPR besides the transcriptional activity on its own promoter and other UPR promoters containing the UPRE (33, 35). However, the low levels of IgM mRNA in XBP1−/− result from the 8-fold increased levels of IRE1P over control; the highly abundant IRE1P cleaves the µ secretory mRNA (49). But a double deletion of XBP1 and IRE1 restores IgM secretion by inhibiting mRNA degradation (49).

Acknowledgments

We thank Dr. O.J. Finn and E. Milcarek for encouragement and the Immunology Department, University of Pittsburgh for seed funding for animal model studies.

Disclosures

The authors have no financial conflicts of interest.

References


